LIVE
 
 
 
 
 
 
 
 
 
 
 
 
Deutsche Börse-Logo
  • Home
  • Aktien
  • Anleihen
  • ETF/ETP
  • Fonds
  • Rohstoffe
  • Zertifikate
  • Nachhaltig
  • News
  • Wissen
  • Einstieg
  • Nachrichten
  • Bekanntmachungen
  • Marktstimmung
18.11.26 11:25:12

Original-Research: K+S AG (von Parmantier & Cie. GmbH): Buy

^

Original-Research: K+S AG - from Parmantier & Cie. GmbH

18.11.2026 / 11:25 CET/CEST

Dissemination of a Research, transmitted by EQS News - a service of EQS

Group.

The issuer is solely responsible for the content of this research. The

result of this research does not constitute investment advice or an

invitation to conclude certain stock exchange transactions.

---------------------------------------------------------------------------

Classification of Parmantier & Cie. GmbH to K+S AG

Company Name: K+S AG

ISIN: DE000KSAG888

Reason for the research: Valuation Upgrade to Buy

Recommendation: Buy

from: 18.11.2026

Target price: 17,50

Last rating change: Hold

Analyst: René Parmantier

PRESS RELEASE

K+S: Parmantier & Cie. Research upgrades to Buy - EUR17.50 target

Valuation upgrade after share-price decline; approximately 35% upside to

unchanged target

Frankfurt am Main, 18 November 2026. Parmantier & Cie. Research upgrades K+S

from Hold to Buy, retaining its EUR17.50 price target. Against the EUR12.97

reference price, the Xetra close on 16 November 2026, this implies

approximately 35% price upside and a 36% expected 12-month total return

including the PCR dividend estimate.

The valuation upgrade follows the share-price decline from around EUR17 to

EUR12-13. PCR sees a more attractive entry point into a cyclical recovery. The

spring season is the next test: PCR expects high capacity utilisation, while

Baltic logistics constraints may restrict effective supply. This is PCR's

assessment, not K+S guidance.

PCR forecasts EBITDA of approximately EUR709m for 2027 and EUR810m for 2028,

around 2% and 15% above Vara consensus dated 14 October 2026. K+S has not

yet issued formal 2027 guidance. PCR expects the clearest cash-flow relief

in 2029, following the completion of Werra 2060 planned for summer 2028.

The share purchase by CFO Dr. Jens Christian Keuthen and Rossmann's larger

disclosed position provide additional context. Rossmann reported a combined

position of 20.04%, comprising 7.98% in direct shares and 12.06% through

instruments. PCR views this as a positive confidence signal, not evidence of

intrinsic value.

Risks remain potash prices, farmer affordability, additional supply, project

execution, energy costs and cash conversion.

Request the full study and join our research mailing list:

For the full study and inclusion on the research mailing list, contact:

research@parmantiercie.com.

Parmantier & Cie. Research | René Parmantier

Independent, unsolicited and unpaid research. This release summarises the

study and does not replace its full risk and conflict-of-interest

disclosures or constitute personalised investment advice. Targets and

forecasts are not guarantees.

You can download the research here:

https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&u=4794bd785d5e4852f263b171a01013a3

Contact for questions:

---------------------------------------------------------------------------

The EQS Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

View original content:

https://eqs-news.com/?origin_id=36cedd21-e338-11f1-b46d-066675bb9927&lang=en

---------------------------------------------------------------------------

2437602 18.11.2026 CET/CEST

°

Nachrichten zu K+S Aktiengesellschaft

Keine News verfügbar

Bitte warten...

News ►

UhrzeitTitel

Newsletter

  • Zur Newsletter Anmeldung
Willkommen an der Deutschen Börse! Um dir das bestmögliche Online-Erlebnis zu ermöglichen, setzen wir auf unserer Webseite Cookies ein. Mit dem Klicken auf "Akzeptieren" erklärst du dich damit einverstanden, dass wir Cookies oder verwandte Technologien verwenden dürfen. Über den Button "Einstellungen" kannst du der Verwendung der genannten Dienste im Einzelnen zustimmen oder widersprechen. Detaillierte Informationen und wie du der Verwendung von Cookies und verwandten Technologien auf dieser Website jederzeit widersprechen kannst, findest du in unseren Datenschutzhinweisen.
Copyright Deutsche Börse
KontaktImpressum
Disclaimer Datenschutz
Markenrechte
Cookie-Einstellungen
Drucken
Charts von
Tradingview Logo
Deutsche Börse-App
App Store
Google Play Store

live.deutsche-boerse.com

  • Aktien
  • Anleihen
  • ETF/ETP
  • Fonds
  • Rohstoffe
  • Zertifikate
  • Nachhaltig
  • Einstieg

News

  • Nachrichten
  • Bekanntmachungen
  • Marktstimmung
  • RSS-Feed
  • Podcasts
  • Newsletter

Wissen

  • Börse besuchen
  • Über die Börsen
  • Wertpapiere
  • Handeln
  • Börsenlexikon
  • Publikationen
  • Events und Webinare

Services

  • Watchlist
  • Portfolio
  • Xetra Realtime für Aktien
  • Xetra Realtime für ETFs
  • Karriere @Börse

Weitere Websites der Gruppe Deutsche Börse

  • Karriere
  • Presse
  • Deutsche Börse
    (Listing und Trading)
  • Deutsche Börse Group
  • Eurex
  • Xetra-Gold

Kontaktieren Sie uns:

  • ► Alle Kontaktadressen für Ihr Anliegen